drugset / Trial / NCT01027416
Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
Completed
59 enrolled
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will help to understand the interaction between estrogen receptor-alpha (ER alpha) and tumor suppressor protein p53 as well as impact on patient tumor gene expression in response to the hormonal therapy Tamoxifen. This information may eventually help select the appropriate therapy for future patients with similar cancer.
Timeline
- Start
- 2009-12-14
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tamoxifen | Small molecule | 20 mg | Oral |